Alzheimer's disease continues to pose a significant challenge to global healthcare systems, with the 7MM reporting approximately 16 million diagnosed prevalent cases in 2023. This rising AD prevalence highlights an urgent need for innovative treatments to mitigate the growing disease burden on both patients and caregivers. The aging global population, coupled with the increasing Alzheimer's disease diagnosis rate, makes it a critical focus for the pharmaceutical industry, driving robust research and development efforts.
In the United States, the disease disproportionately affects females, with 4.6 million women diagnosed in 2023 compared to 2.3 million men. T...
